WINTERTHUR, Switzerland--(BUSINESS WIRE)--Cardiola AG announced today it is collaborating with The Heart and Diabetes Center North Rhine-Westphalia, Ruhr University of Bochum, Bad Oeyhausen, Germany, in a study of the Company’s CE-Marked m.pulse® system. The study’s purpose is to investigate the utility of “Muscular CounterPulsation” (“MCP”) in patients with early-stage heart failure. MCP was previously only available in a clinical setting. Now, m.pulse® is the world’s first and only device enabling chronic heart failure (CHF) patients to receive MCP therapy at home. Principal investigator for the study is Univ.-Prof. Dr. med. Dieter Horstkotte.
